FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

ashington,	D.C.	20549	
------------	------	-------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
	or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

						` '				. ,								
Name and Address of Reporting Person*     Schenkein David P					2. Issuer Name <b>and</b> Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [ AGIO ]							(Ch	Relationship leck all appli X Directo	cable)	Pers	son(s) to Issuer		
					AGIC	' ]								(give title		Other (s	pecify	
` ,	(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year)							below)			below)		
88 SIDNEY STREET					05/20/2021													
OU SIDNET STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Lin	,	filed by One	Dono	rting Doroo	_	
CAMBR	IDGE M	A	02139								Form	Form filed by More than One Reporting						
(City)	(S	tate)	(Zip)										Perso	ıı				
		Tab	le I - Non-I	Derivat	tive S	ecuritio	es A	cquired, D	Disp	osed o	of, or Be	neficial	ly Owned	d				
Date			. Transact Date Month/Day	Execution Date,		Code (In					Benefici Owned I	es For ially (D) Following (I) (		Direct Conditions of the Direct Endirect Entr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		ansaction(s) str. 3 and 4)			Instr. 4)		
		Т	able II - De	erivativ .g., put	/e Se ts, ca	curities Ils, war	Acc rant	uired, Dis	spo s, co	sed of onverti	, or Ben ble secu	eficially ırities)	Owned					
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Co	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Co	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Restricted stock unit	(1)	05/20/2021		A	A	1,585		(2)		(2)	Common stock	1,585	\$0	1,585		D		
Stock options (right to	\$56.76	05/20/2021		A	A	8,888		(3)	05	5/20/2031	Common stock	8,888	\$0	8,888		D		

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested
- 3. This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022.

## Remarks:

/s/ William Cook, as Attorney in Fact for David Schenkein

05/24/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.